Hot off its first approval this summer in psoriasis, Arcutis Biotherapeutics’ roflumilast foam 0.3%, approved in cream form under the brand name Zoryve, is out to prove it’s no one-trick pony in itch.
Arcutis Biotherapeutics and Kowa Pharmaceuticals are cutting ties on their U.S. marketing partnership around Arcutis’ Zoryve ...
It’s been said before and it’s true: a healthy scalp is key to healthy hair. But for those dealing with pesky and sometimes painful scalp conditions like seborrheic dermatitis, that can be easier said ...
WESTLAKE VILLAGE, Calif, June 26, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company dedicated to developing meaningful innovations in ...
First FDA-approved medication for atopic dermatitis (eczema), plaque psoriasis, and seborrheic dermatitis to win prominent “Breakthrough Award” ZORYVE is the number one prescribed branded topical ...
NEW YORK CITY -- A topical phosphodiesterase-4 (PDE4) inhibitor produced rapid improvement in seborrheic dermatitis, particularly scalp lesions, a randomized clinical trial showed. Two-thirds of ...
New data from the Phase 3 INTEGUMENT-OLE long-term open label study show durable improvement in the signs and symptoms of atopic dermatitis (AD), including almost half of participants achieving no or ...
Under the terms of the Termination Agreement, Kowa will cease all sales and promotions of ZORYVE and Arcutis will not be required to make any further payments. The Company expects to remain cash flow ...
Credit: Arcutis. Zoryve cream contains roflumilast, a phosphodiesterase type 4 inhibitor. Zoryve (roflumilast) cream 0.15% is now available for the topical treatment of mild to moderate atopic ...
Credit: Arcutis. The approval was supported by data from the phase 3 INTEGUMENT-1 and INTEGUMENT-2 trials. The Food and Drug Administration (FDA) has approved Zoryve ® (roflumilast) cream 0.15% for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results